Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 10/20 | 0.62 |
| ▸ | RAB9A | P51151 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | STAT1 | P42224 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3221922 | 0.88 | NPC1 (0.73) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL17155529 | 0.82 | RAB9A (0.53) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL28756192 | 0.81 | NPC1 (0.65) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL10759780 | 0.81 | NPC1 (0.81) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL27647698 | 0.81 | PKM (0.54) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL11542701 | 0.79 | KDM4E (0.67) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL9704263 | 0.79 | RAB9A (0.57) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL12535986 | 0.79 | HTT (0.67) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL459011 | 0.79 | KDM4E (1.00) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL16355305 | 0.78 | KDM4E (0.59) | KDM4EHPGDNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021106733-A1 | POWDERED SOLID COSMETIC PRODUCT | 株式会社 資生堂 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020241357-A1 | PERSONAL CARE COMPOSITION AND MALODOR SUPPRESSION METHOD | 株式会社 資生堂 | 2020-12-03 | — | — | WO | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| CN-1761787-A | Oxidation system comprising macrocyclic metal complexes, method for the production and use thereof | LANXESS B V (NL) | 2006-04-19 | — | — | CN | disclosed |
| CN-1272782-A | Skin compositions for external use | SHISEIDO CO LTD (JP) | 2000-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | KDM4E 3777/4885HPGD 2220/4885NPC1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.